COMPLETED

CCS-AMI Staging Diagnosis by High-sensitivity Cardiac Troponin-I

Talk to us

Conditions

Acute Myocardial Infarction (AMI)Hemorrhagic Myocardial InfarctionCCS-AMI StagesHigh sensitivity Cardiac Troponin-INon-hemorrhagic MI

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

MIRON-CCS is a multicenter retrospective diagnostic study designed to evaluate the role of high-sensitivity cardiac troponin I (hs-cTnI) in the diagnosis and clinical stage classification of acute myocardial infarction (AMI) as defined by the Canadian Cardiovascular Society (CCS) AMI staging system. The study retrospectively analyzes biomarker data from patients diagnosed with AMI across multiple institutions, focusing on whether hs-cTnI levels-measured at specific time points-can reliably identify and stratify patients into CCS-defined AMI clinical stages (Stage 1 to Stage 4). It aims to correlate hs-cTnI kinetics and peak levels with clinical stage, presentation patterns, and outcomes. This trial seeks to offer a biomarker-based alternative to imaging-heavy staging, potentially streamlining early diagnosis and therapeutic triage for AMI patients in varied clinical settings.

Official Title

High-Sensitivity Cardiac Troponin I as a Diagnostic Marker for CCS-AMI Clinical Stage Classification in Acute Myocardial Infarction: A Retrospective Multicenter Study

Quick Facts

Study Start:2023-01-10
Study Completion:2025-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT07163988

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 79 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18-79 years
  2. * Index STEMI
  3. * Coronary angiogram with PCI to occur irrespective of the onset of the symptoms.
  4. * Ability to provide informed consent for themselves
  1. * History of prior myocardial infarction,
  2. * Cardiogenic shock,
  3. * Patients who present with current cardiac arrest
  4. * Any contraindication to cardiac CMR (claustrophobia, pacemaker or cardiac defibrillator, known allergy to gadolinium),
  5. * Presence of permanent atrial fibrillation,
  6. * Unconscious patient,
  7. * Severe renal insufficiency (creatinine clearance ≤ 30 ml/min/m2 or renal replacement therapy),
  8. * Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test.

Contacts and Locations

Study Locations (Sites)

Medical Imaging Research Institute
Indianapolis, Indiana, 46202
United States

Collaborators and Investigators

Sponsor: Indiana University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-10
Study Completion Date2025-09-30

Study Record Updates

Study Start Date2023-01-10
Study Completion Date2025-09-30

Terms related to this study

Keywords Provided by Researchers

  • Hemorrhagic Myocardial Infarction
  • CCS-AMI Stages
  • High sensitivity Cardiac Troponin-I
  • Non-hemorrhagic MI

Additional Relevant MeSH Terms

  • Acute Myocardial Infarction (AMI)